title: The expression of ARHI in pT2a and pT2b stage gastric cancer and its             clinical significance.
abstract: ARHI is a novel tumor suppressor gene located on chromosome 1p31. Downregulation             of ARHI expression has been detected in many types of cancer. However, the effects             of ARHI in gastric cancer remain unclear. The aim of this study was to identify             the relationship between ARHI expression and gastric cancer clinicopathological             features. In this study, 81 pT2 stage gastric cancer specimens were subclassified             by pT2a and pT2b stage. ARHI mRNA and protein levels were evaluated by real-time             PCR and western blot analysis, respectively. Methylation plays an important role             in suppressor gene silencing. We utilized methylation-specific PCR to identify             the status of CpG islands in the ARHI gene. We used immunohistochemistry to determine             the expression of the protein and analyzed clinicopathological features. The levels             of ARHI mRNA in gastric cancer were lower compared to normal tissues (P<0.01).             Similarly, the levels of ARHI protein in the cancer specimens were lower (P<0.05).             DNA hypermethylation was identified in 79.1% of gastric cancer specimens without             ARHI expression. Immunohistochemistry results were significantly correlated with             the pT2 category (P<0.05). The cumulative survival rate of patients with ARHI             expression was significantly higher compared to those without ARHI expression             (P<0.05). ARHI as a suppressor is not only an important factor in the pathogenesis             of gastric cancer, but also a potential factor for tumor aggravation. ARHI expression             in gastric cancer can be employed to indicate favorable prognosis for the disease.
authors.affiliation: Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang 110001, PR China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Xian-Min
authors.initials: XM
authors.lastname: Bu
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Ning
authors.initials: N
authors.lastname: Zhang
authors.forename: Cheng-Hai
authors.initials: CH
authors.lastname: Zhao
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics; D018899:CpG Islands; D019175:DNA Methylation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011401:Promoter Regions, Genetic; D013274:Stomach Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D020741:rho GTP-Binding Proteins / Q000235:genetics* / Q000378:metabolism*
chemical_list: D014408:Biomarkers, Tumor; C117386:DIRAS3 protein, human; D020741:rho GTP-Binding Proteins